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José Luis Ferreiro, MD*yGuidelines provide a Class IA recommendation for using
platelet P2Y12 receptor inhibitors in patients with acute
coronary syndromes (ACS) and undergoing percutaneous
coronary interventions (PCI) (1–3). Clopidogrel is the most
utilized P2Y12 receptor inhibitor. However, despite its
beneﬁts, numerous studies have shown inconsistency in the
efﬁcacy of clopidogrel to prevent atherothrombotic events
(4,5). Studies of platelet function testing (PFT) have shown
variability in the pharmacodynamic response to clopidogrel,
and studies of genetic testing (GT) have identiﬁed
individuals with genetic polymorphisms that may affect
clopidogrel absorption, metabolism, and ultimately its
pharmacodynamic effects (4,6). Importantly, PFT and GT
have prognostic implications (4,6). In particular, patients
with high on-treatment platelet reactivity (HPR) or
patients who have genetic variants associated with reduced
clopidogrel metabolism (e.g., cytochrome P450 [CYP]
2C19 loss-of-function [LOF] alleles), have an increased
risk of ischemic events, particularly stent thrombosis.
Similarly, patients with low on-treatment platelet reactivity
or patients with genetic variants associated with increased
clopidogrel metabolism have been associated with bleeding
risk (6). These observations have led to PFT and GT being
considered as tools to help guide physicians to individualize
antiplatelet treatment regimens with the goal of
minimizing ischemic and bleeding complications. Whereas
tailoring treatments based on biomarkers and genes is an
emerging ﬁeld in multiple areas of medicine, there are
numerous encumbrances to justify the routine application
of PFT and GT to test for clopidogrel-mediated effects,
underscoring that these tests should be still reserved as
research tools.
The lack of large-scale, prospective, randomized study
data demonstrating that modifying antiplatelet therapybased on PFT or GT has a meaningful impact on clinical
outcomes have led guideline recommendations to be poorly
supportive of their use in clinical practice (Table 1) (1–3).
Nevertheless, it is important to emphasize that the
research conducted has been pivotal to advance our
understanding on the role of antiplatelet therapy in
prevention of ischemic events and has set the basis for
promoting new treatment options, particularly in high-risk
settings. Numerous studies have shown that platelet
reactivity can be modiﬁed with intensiﬁed antiplatelet
treatment in patients with HPR or with CYP2C19 LOF
alleles, which can be easily and rapidly assessed using
point-of-care assays available for both PFT and GT (8).
However, although some small-scale pilot studies have
proven that modifying levels of platelet reactivity can
improve outcomes (9,10), these preliminary ﬁndings were
not conﬁrmed in large-scale clinical trials. Therefore,
a critical analysis of the data is important to understand
why these tests are not ready for routine use as well as to
deﬁne areas of future investigation.
The GRAVITAS (Gauging Responsiveness With a Ver-
ifyNow Assay–Impact on Thrombosis and Safety) trial (11)
was the ﬁrst large-scale clinical trial to test the clinical
impact of high- versus standard-dose clopidogrel in HPR
patients identiﬁed by the VerifyNow P2Y12 assay. The
trial was conducted in patients (n ¼ 2,214) undergoing
PCI with drug-eluting stents (DES); many were
undergoing complex interventions. However, the trial
failed to observe any beneﬁt of intensiﬁed antiplatelet
treatment, showing identical 6-month ischemic endpoints
in the 2 treatment arms (2.3% vs. 2.3%). Numerous
interpretations can be made to explain these ﬁndings (e.g.,
inadequacy of high-dose clopidogrel to modify platelet
reactivity, timing of PFT, PFT cutoff value), although the
low event rates, which can be largely attributed to the low
clinical risk proﬁle of the study population, composed
mostly of stable coronary artery disease (CAD) patients,
may have represented the main contributor. Contrary to
GRAVITAS, high event rates were observed in the
RECLOSE 2-ACS (Responsiveness to Clopidogrel and
Stent Thrombosis 2-ACS) study, an all-comers ACS
registry showing a 14.6% event rate at 2 years among
HPR patients (12). Using high-dose clopidogrel or
ticlopidine in HPR patients did not affect outcomes in
this study, suggesting that even higher clopidogrel doses
Table 1
Guideline Recommendations on the Use of
Platelet Function and Genetic Testing
2011 ACCF/AHA Focused Update of the Guidelines for the Management of
Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2)
Platelet Function Testing
Class IIb
Platelet function testing to determine platelet inhibitory response in patients
with UA/NSTEMI (or, after ACS and PCI) on thienopyridine therapy may be
considered if results of testing may alter management. (Level of Evidence: B)
Genetic Testing
Class IIb
Genotyping for a CYP2C19 loss of function variant in patients with UA/NSTEMI
(or, after ACS and with PCI) on clopidogrel therapy might be considered if
results of testing may alter management. (Level of Evidence: C)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention (3)
Platelet Function Testing
Class IIb
1. Platelet function testing may be considered in patients at high risk for poor
clinical outcomes. (Level of Evidence: C)
2. In patients treated with clopidogrel with high platelet reactivity, alternative
agents, such as prasugrel or ticagrelor, might be considered. (Level of
Evidence: C)
Class III: no beneﬁt
1. The routine clinical use of platelet function testing to screen patients treated
with clopidogrel who are undergoing PCI is not recommended. (Level of
Evidence: C)
Genetic Testing
Class IIb
1. Genetic testing might be considered to identify whether a patient at high risk
for poor clinical outcomes is predisposed to inadequate platelet inhibition
with clopidogrel. (Level of Evidence: C)
2. When a patient predisposed to inadequate platelet inhibition with clopidogrel is
identiﬁed by genetic testing, treatment with an alternate P2Y12 inhibitor (e.g.,
prasugrel or ticagrelor) might be considered. (Level of Evidence: C)
Class III: no beneﬁt
1. The routine clinical use of genetic testing to screen patients treated with
clopidogrel who are undergoing PCI is not recommended. (Level of Evidence:
C)
ESC Guidelines for the Management of Acute Coronary Syndromes in Patients
Presenting Without Persistent ST-Segment Elevation (4)
Platelet Function and Genetic Testing
Class IIb
1. Increasing the maintenance dose of clopidogrel based on platelet function
testing is not advised as routine, but may be considered in selected cases.
(Level of Evidence: B)
2. Genotyping and/or platelet function testing may be considered in selected
cases when clopidogrel is used. (Level of Evidence: B)
ACCF/AHA ¼ American College of Cardiology Foundation/American Heart Association; ACS ¼
acute coronary syndromes; CYP ¼ cytochrome P450; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; PCI ¼ percutaneous coronary intervention; SCAI ¼ Society for Cardiovascular
Angiography and Interventions; UA ¼ unstable angina.
Figure 1
Impact of Platelet Reactivity on the
Balance Between Safety and Efﬁcacy
On-treatment platelet reactivity is associated with the risk of both ischemic and
bleeding events. Therefore, antiplatelet treatment regimens need to be within
a range (“therapeutic window”) that is not too high or too low in order to reduce the
risk of ischemic and bleeding events, respectively. The therapeutic window of on-
treatment platelet reactivity may potentially vary according the patient phenotype,
such as clinical presentation (acute coronary syndrome [ACS] vs. stable patient),
glucose control (diabetes mellitus [DM] vs. non–diabetes mellitus patient), renal
function (chronic kidney disease [CKD] vs. normal renal function), and age (elderly
vs. nonelderly). Figure illustration by Craig Skaggs.
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S22(>150 mg) or the more novel and potent P2Y12 receptor
inhibitors (prasugrel or ticagrelor) should be considered to
ensure that intensiﬁed platelet inhibition is achieved (8). A
recent study showed that 225- to 300-mg daily clopidogrel
maintenance doses are required to achieve levels of platelet
reactivity below thresholds associated with thrombotic risk
in patients who are carriers of 1 CYP2C19 LOF, a dosing
regimen that, however, had a negligible impact in patients
who were carriers of 2 LOF alleles (13).
The clinical implications of using a novel P2Y12 inhibitor
was tested in the TRIGGER-PCI (Testing Platelet Reac-
tivity in Patients Undergoing Elective Stent Placement on
Clopidogrel To Guide Alternative Therapy With Prasugrel)trial (14) in which HPR patients with stable CAD
undergoing elective PCI with DES were randomized to
treatment with prasugrel versus clopidogrel. However, after
randomizing 423 HPR patients, the trial was interrupted
for futility as only a single ischemic event had occurred.
Although there was no signiﬁcant increase in major
bleedings, it could not be excluded that exposing these
stable CAD patients to prolonged treatment with
intensiﬁed P2Y12 receptor blockade could result in harm.
It may be argued that in both GRAVITAS and
TRIGGER-PCI, patients were not enrolled until after
successful PCI and that randomizing before PCI could
have potentially affected peri-procedural event rates.
However, this approach presents inherent logistic
challenges, in addition to the fact that the beneﬁt of
P2Y12 receptor inhibitor pre-loading remains disputable.
Whereas these trial results may be disappointing for
clinicians sharing enthusiasm toward routine testing, they
should be viewed positively given the very low event rates
in stable CAD patients undergoing PCI using standard
clopidogrel therapy, despite their high biological and/or
angiographic risk. The preceding considerations have some
potential for PFT and GT in populations with high event
rates, such as ACS, where a measurable treatment effect is
more likely to be appreciated.
Most recently, the ARCTIC (Assessment by a Double
Randomization of a Conventional Antiplatelet Strategy
Versus a Monitoring-Guided Strategy for Drug-Eluting
Stent Implantation and of Treatment Interruption Versus
Continuation One Year After Stenting) trial (15) was
reported. This study evaluated a strategy of systematic
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S23platelet-function monitoring for the purpose of adjusting
treatment in patients with a poor response to aspirin,
thienopyridine (clopidogrel or prasugrel), or both, as
compared with a conventional approach in which similar
treatment was given to all patients, without platelet-
function assessments. A total of 2,440 patients (27%
ACS) scheduled for coronary stenting were randomized.
In the monitoring group, HPR in patients treated with
clopidogrel (34.5% of patients) or aspirin (7.6%) led to the
administration of an additional bolus of clopidogrel,
prasugrel, or aspirin with glycoprotein IIb/IIIa inhibitors
during the procedure. The primary endpoint (composite of
death, myocardial infarction, stent thrombosis, stroke, or
urgent revascularization at 1 year) was numerically higher
in the monitoring (34.6%) compared with the
conventional (31.1%) treatment group (hazard ratio: 1.13,
95% conﬁdence interval: 0.98 to 1.29; p ¼ 0.10).
Overall, these ﬁndings raise several important concerns on
implementing routinely PFT or GT in clinical practice. In
addition, knowing the best test to consider for tailoring
treatment remains an unsolved issue. GT presents the
advantage over PFT in that genetic background is a constant
and does not vary. However, an individual’s genetic make-up
is only 1 piece of the puzzle contributing to the pharma-
codynamic response of any drug, including clopidogrel (e.g.,
CYP2C19 contributes to 5% to 12% of clopidogrel response
variability), and other factors (e.g., clinical and cellular) also
remain key determinants (4,5,7). Levels of platelet reactivity
as detected by PFT have the advantage of being a moreFigure 2
Clopidogrel Responsiveness in Patients With and Without D
Within 30 Days in the ADAPT-DES Trial
Patients with deﬁnite/probable stent thrombosis have signiﬁcantly higher on-treatment pl
assay, compared with patients without stent thrombosis in the ADAPT-DES (Assessment
considerable overlap in platelet function proﬁles between the 2 groups, limiting the abilit
range; PRU ¼ P2Y12 reactivity unit. Adapted, with permission, from Stone (16).representative intermediate phenotype of thrombotic risk
than an individual gene is. However, uncertainties remain on
the best PFT to be used as well as the optimal cutoff value to
predict adverse events (4,5,7). This is further challenged by
the fact that levels of platelet reactivity vary over time and
may have different prognostic signiﬁcance according to the
speciﬁc population under consideration (4,5,7). Investiga-
tions have attempted to deﬁne a “therapeutic window” of
platelet reactivity that can minimize bleeding and ischemic
implications, but more research is warranted. Indeed, the
intrinsic differences in thrombotic and hemostatic process in
different clinical settings (ACS, diabetes mellitus, chronic
kidney disease), which vary according to age, race, and sex,
and their contributing role on clinical outcomes may also
suggest the need for dedicated studies to identify therapeutic
windows that are “population-speciﬁc” (Fig. 1).
Reﬁning the prognostic signiﬁcance of results from PFT
and GT according to the clinical setting may potentially add
to their predictive values, which to date have shown to be
modest, making them less than ideal to be considered for
risk stratiﬁcation. This was recently assessed in the
ADAPT-DES (Assessment of Dual Antiplatelet Therapy
With Drug-Eluting Stents) trial (NCT00638794), the larg-
est prospective multicenter observational study of unselected
clopidogrel-treated patients (n ¼ 8,575) undergoing DES
implantation in whom PFT with the VerifyNowP2Y12
assay was performed (16). The trial observed 39 deﬁnite/
probable stent thromboses at 30 days (0.46%), mostly
(n ¼ 30) occurring in ACS patients. Although PFTeﬁnite/Probable Stent Thrombosis
atelet reactivity and reduced platelet inhibition, as measured by the VerifyNow P2Y12
of Dual Antiplatelet Therapy With Drug-Eluting Stents) trial. However, there is
y to discriminate patients at risk of developing stent thrombosis. IQR ¼ interquartile
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thrombosis (w3-fold risk of stent thrombosis in HPR
patients), using an accepted cutoff value, the test had
a sensitivity of 74.4%, speciﬁcity 57.4%, positive predictive
value 0.8%, and negative predictive value 99.8%. Overall,
the considerable overlap in platelet reactivity between
patients with and without stent thrombosis, combined
with the very low event rates, limit the ability of PFT to
discriminate patients at risk of developing stent thrombosis
(Fig. 2). Therefore, it is unlikely that functional testing
may provide useful information to guide clinical decision
making in most individual patients for the prevention of
ischemic events. Such limited incremental clinical utility is
also in line with the modest increase in predictive accuracy
of adding results of PFT and GT to other established
predictors of poor outcomes (17,18).
In summary, currently available evidence cannot
support the routine clinical use of PFT and GT, as is also
reﬂected in practice guidelines (1–3), suggesting the need
for more studies before these tests can be recommended
to guide antiplatelet therapy. However, until results of
large-scale studies demonstrating not only the efﬁcacy but
also the safety, including bleeding and nonhematological
side effects, of adjustment of antiplatelet treatment are
available, PFT and GT should be considered mostly as
research tools. Their clinical use should be limited to
patients at high risk for poor clinical outcomes (e.g.,
scenarios in which a thrombotic event may be cata-
strophic or lethal such as in unprotected left main,
bifurcating left main, last patent coronary vessel) and only
if this will result in a change in therapy. Overall, clini-
cians should abide by the more sound ﬁndings of large-
scale clinical trials to guide them in their best choice of
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S25Perspective:
Platelet and Genetic Testing for
Clopidogrel Hyporesponsiveness
Use as a Clinical Tool
Matthew J. Price, MDPlatelet activation and aggregation are the proximate causes
of thrombotic events after percutaneous coronary intervention
(PCI). TheP2Y12 antagonist clopidogrel, in combinationwith
aspirin, signiﬁcantly reduces the risk of post-PCI cardiovas-
cular events. Platelet function tests canmeasure the antiplatelet
effect of clopidogrel and the other P2Y12 antagonists prasugrel
and ticagrelor (1). There is wide variation in the antiplatelet
effect of clopidogrel among individuals, in large part due to
genetic variation in the CYP2C19 enzyme that mediates the
biotransformation of the pro-drug into active metabolite (2).
Herein, I review the evidence that supports the clinical utility
of platelet function testing (PFT) and genotyping, and set
forth a rational construct for their use in clinical practice in
the absence of deﬁnitive data from randomized clinical trials
(RCTs).Development of the Oral P2Y12 Antagonists
Although PFT may appear novel to the clinician, it has played
a critical role in the development of the approved P2Y12
antagonists. These agents were identiﬁed and their doses
selected based upon the hypothesis that adenosine diphos-
phate–induced platelet aggregation has a strong relationship
with clinical outcomes. The clopidogrel 75-mg maintenance
dose (MD)was selected for initialRCTs because it had a similar
effect on adenosine diphosphate–induced platelet aggregation
as ticlopidine (3), and this resulted in similar ischemicoutcomes.
The doses of prasugrel and ticagrelor tested in phase 2/3 trials
were based upon PFT results that showed greater inhibition
of platelet aggregation and less hyporesponsiveness compared
with clopidogrel (4,5). The resulting superior clinical efﬁcacy
of these agents compared with clopidogrel based on this
modeling argues that the measured level of platelet reactivity
reﬂects a key mechanism for thrombosis. Although the
aforementioned studies used light transmittance aggregometry
to measure platelet function, the ﬁndings are consistent with
those observed with the VerifyNow P2Y12 test (Accumetrics,
San Diego, California), including in a PLATO (PLATelet
inhibition and patient Outcomes) substudy (1,6).Platelet Reactivity, Genotype,
and Clinical Outcomes
Prospective studies and a post hoc RCT analysis involving in
total >14,000 patients have examined the association
between clopidogrel effect measured by the VerifyNowP2Y12 test and post-PCI thrombotic events (Table 1).
Several conclusions can be drawn from these ﬁndings: 1)
on-treatment reactivity (OTR) is strongly associated with
death, myocardial infarction (MI), and stent thrombosis in
both acute coronary syndrome (ACS) patients and those
with stable coronary artery disease (CAD) (7,8); 2)
a reasonable threshold to identify at-risk patients (“high”
OTR) is a P2Y12 reaction unit (PRU) level >208w230
(7–9); 3) patients with high OTR have a 3- to 5-fold
higher adjusted risk of stent thrombosis at 30-day and longer-
term follow-up (7,9); and 4) stent thrombosis events are largely
attributable to high OTR (9). Similar thresholds identify
prasugrel-treated patients at risk for thrombotic events,
indicating that OTR is the primary arbiter of outcome, rather
than the drug itself (10).
Clopidogrel active metabolite levels correlate withCYP2C19
loss-of-function (LOF) allele carriage in a codominantmanner
(2). Numerous studies and meta-analyses have demonstrated a
signiﬁcant association between CYP2C19 LOF allele carriage
and increased risk of cardiovascular events, including
mortality, in clopidogrel-treated patients (2). Carriers of 1
and 2 LOF alleles undergoing PCI who are treated with
clopidogrel have an approximately 3- and 4-fold risk of stent
thrombosis, respectively. However, the inﬂuence of CYP2C19
genotype is less apparent in patients who are treated for
indications other than coronary stenting (2). Meta-analyses
that included studies that tested clopidogrel in such settings
(e.g., atrial ﬁbrillation) failed to identify an association
between genotype and overall cardiovascular events, although
the relationship between CYP2C19 genotype and MI or stent
thrombosis persisted (11).
Prognostic Utility
Diagnostic tests are used to determine whether a patient has
a disease at the time the test is performed (e.g., stress imaging for
the presence or absence of obstructive CAD). By contrast,
platelet function andCYP2C19 genotype are prognostic, that is,
they are used to determine whether a patient is at increased risk
of experiencing a thrombotic event over time. The appropriate
statistical methods to assess the utility of diagnostic and prog-
nostic tests differ (Table 2). Positive predictive values can be
misleading when applied to prognostic tests, because they
depend on the incidence of the outcome, which is in turn
time-dependent (12). The area under the curve (AUC) on
receiver-operating characteristic curve analysis measures
predictive accuracy, that is, the ability of a test to discriminate
between patients who will or will not have a clinical event.
Both high OTR and genotype have signiﬁcant predictive
accuracy and improve the AUC of post-PCI risk models.
Although the absolute improvements in AUC are modest,
even a strong predictor may have limited impact when added
to a risk model (13). Requiring a new marker to substantially
improve the AUC would eliminate most risk factors currently
employed for cardiovascular risk prediction, including lipids,
blood pressure, and smoking (13). Reclassiﬁcation analyses,
Table 1
Recent Prospective, Observational Studies of the Association Between OTR While Receiving Clopidogrel and
CV Events After PCI
First Author/Study
(Ref. #) N Population Studied Platelet Function Test Deﬁnition of High OTR
Adjusted Hazard Ratio
(95% Conﬁdence Interval)
Brar et al. (7) 3,059 Stable CAD and ACS VerifyNow P2Y12 PRU >230 Death, MI, or ST (primary): 2.10 (1.62–2.73)
Death: 1.66 (1.04–2.68)
ST: 3.11 (1.50–6.46)
RECLOSE-2 ACS (9) 1,682 ACS LTA (ADP) Maximal platelet
aggregation
>70%
Death, MI, urgent TVR, or stroke (primary): 1.49 (1.08–2.05)
Cardiac death: 1.81 (1.18–2.76)
2-yr ST: 2.02 (1.03–3.93)
GRAVITAS (8) 2,796 90% biomarker
negative
VerifyNow P2Y12 PRU >208 6-month CV death, MI, ST (primary): 1.85 (0.96–3.57)
ADAPT-DES 8,575 14.5% NSTEMI,
9.5% STEMI
VerifyNow P2Y12 PRU >208 Deﬁnite/probable ST at 30 days (primary): 3.00 (1.39–6.49)
Deﬁnite ST at 30 days: 5.36 (1.89–15.21)
ACS ¼ acute coronary syndrome; ADAPT-DES ¼ Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents; ADP ¼ adenosine diphosphate; CAD ¼ coronary artery disease; CV ¼ cardiovascular;
GRAVITAS ¼ Gauging Responsiveness with A VerifyNow assay–Impact on Thrombosis And Safety; LTA ¼ light transmittance aggregometry; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-elevation
myocardial infarction; OTR ¼ on-treatment platelet reactivity; PCI ¼ percutaneous coronary intervention; PRU ¼ P2Y12 reaction units; RECLOSE-2 ¼ Responsiveness to Clopidogrel and Stent Thrombosis–2
ACS; ST ¼ stent thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; TVR ¼ target vessel revascularization.
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accurately stratiﬁes individuals into higher- or lower-risk
categories, may be a better approach to assess prognostic
utility. OTR according to the VerifyNow P2Y12 test
signiﬁcantly improves net reclassiﬁcation for major adverse
cardiovascular events (7), supporting the signiﬁcant prognostic
utility of PFT above and beyond current risk models.Impact on Clinical Outcomes
PFT and genotype provide actionable data: prasugrel
and ticagrelor are not dependent on CYP2C19 and effec-
tively suppress platelet reactivity in patients with high
on-clopidogrel reactivity. Small, randomized studies have
demonstrated proof of principle that PFT-guided therapy
reduces the risk of cardiovascular events compared with
conventional therapy (14,15). Three larger RCTs have been
performed. In the GRAVITAS (Gauging Responsiveness
with A VerifyNow assay–Impact on Thrombosis AndTable 2
Assessments to Determine the Clinical Utility of
a Diagnostic or Prognostic Marker
Type of Use Measure Description Examples
Diagnostic testing
Test characteristics Sensitivity and speciﬁcity
Positive predictive value
Negative predictive value
Discrimination ROC curve (AUC, c-statistic)
Likelihood ratio
Risk prediction
Association Odds ratio
Hazard ratio
Relative risk
Discrimination ROC curve (AUC, c-statistic)
Calibration
Reclassiﬁcation Net reclassiﬁcation improvement
Integrative discrimination index
Adapted, with permission, from Pletcher MJ, Pignone M. Evaluating the clinical utility of
a biomarker: a review of methods for estimating health impact. Circulation 2011;123:1116–24.
AUC ¼ area under the curve; ROC ¼ receiver-operating characteristic.Safety) trial, a ﬁxed clopidogrel 150-mg daily MD did not
reduce the risk of cardiovascular events in patients with high
OTR 12 to 24 h after PCI; in addition to low event rates, an
insufﬁcient antiplatelet effect appears to have contributed to
the lack of clinical efﬁcacy (8,16). The TRIGGER-PCI
(Testing Platelet Reactivity in Patients Undergoing Elec-
tive Stent Placement on Clopidogrel to Guide Alternative
Therapy With Prasugrel) trial randomly assigned patients
with high on-clopidogrel reactivity after nonurgent PCI to
either prasugrel or standard-dose clopidogrel and was
terminated prematurely due to a lower-than-expected event
rate (17). The dropout rate after open-label PFT was high
(32% of patients), and enrolled patients had low-risk
procedural characteristics, suggestive of selection bias. The
ARCTIC (Conventional Antiplatelet Strategy Versus
a Monitoring-Guided Strategy for Drug-Eluting Stent
Implantation and of Treatment Interruption Versus
Continuation One Year After Stenting) trial was an open-
label RCT that tested whether, compared with
conventional management, outcomes would be improved
if the results of PFT were routinely provided to clinicians
(18). Most enrolled patients underwent nonurgent PCI.
Patients were treated according to operator discretion in
both treatment groups, although general recommendations
were provided for antiplatelet adjustment in the PFT
group. Among the patients with high OTR in whom the
operators chose to adjust therapy, the most frequent
interventions were glycoprotein IIb/IIIa inhibitors at the
time of the procedure and clopidogrel 150-mg MD post-
procedure. At 1-year follow-up, the rate of the primary
endpoint, driven by periprocedural MI deﬁned by a single
troponin measurement 6 h post-PCI, did not differ
between treatment groups; the rates of out-of-hospital
events, including stent thrombosis, were low and similar
between groups. The results of ARCTIC are consistent
with that of GRAVITAS and TRIGGER-PCI in that
out-of-hospital event rates in patients undergoing
nonurgent PCI are in general low, irrespective of OTR.
The primary intervention in the PFT group, clopidogrel
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S27150-mg dailyMD, was shown inGRAVITAS to provide an
antiplatelet effect associated with improved outcome in only
a minority of patients (8). The clinical efﬁcacy of PFT in
patients undergoing PCI for ACS remains unaddressed by
these trials.
Rationale for Clinical Use
In the absence of deﬁnitive RCTs, the prognostic utility of
PFT and genotyping supports an individualized approach to
their use in practice (Fig. 1).
Acute coronary syndrome. The American College of
Cardiology Foundation/American Heart Association
Guidelines for Unstable Angina/Non-STEMI and for PCI
do not explicitly endorse one P2Y12 antagonist over another
(19,20). Clinicians must weigh the ischemic beneﬁt and
bleeding risk of intensive platelet inhibition when consid-
ering the use of prasugrel or ticagrelor. PFT or genotyping
can help guide antiplatelet selection. Ischemic event rates on
clopidogrel are a function of OTR (Table 1, Fig. 2). Patients
with lower OTR (e.g., <208 PRU) are at signiﬁcantly less
risk, and therefore, the absolute risk reduction with
prasugrel or ticagrelor will necessarily be attenuated in
these patients (Fig. 2). The cost effectiveness of these
newer agents will in turn be diminished, particularly when
compared with generic clopidogrel.Figure 1 PFT in Clinical Practice
In the setting of acute coronary syndrome (ACS), platelet function testing (PFT) can ident
intervention (PCI) on clopidogrel in whom the net clinical beneﬁt of newer oral P2Y12 antago
absolute event rates can identify those in whom more intensive antiplatelet therapy coul
decision points that have not been deﬁnitively examined in randomized clinical trials. PRStable CAD. Both OTR and the CYP2C19 genotype
are strong risk factors for major adverse cardiovascular
events after nonurgent PCI (2,7,8). The GRAVITAS,
TRIGGER-PCI, and ARCTIC trials all illustrate that
post-discharge event rates after elective PCI are generally
low in patients with high OTR. Routine intensiﬁcation of
antiplatelet therapy according to platelet function or geno-
type may not be helpful, as the absolute reduction in
ischemic event rates could be equaled or exceeded by greater
bleeding. Yet, thrombotic risk is heterogeneous among el-
ective PCI patients, and potential reductions in thrombotic
event rates in higher-risk patients may outweigh the
approximate 0.5% increase in non–coronary artery bypass
graft–related major bleeding observed with prasugrel and
ticagrelor. A careful assessment of the overall ischemic risk
for each patient can therefore help identify the appropriate
patient to test and treat. The reﬁnement of risk models
incorporating PFT and/or genotyping that can identify
nonurgent PCI patients who may derive net clinical beneﬁt
from individualized therapy would be helpful in this regard.
Conclusions
The primary critique of individualized antiplatelet therapy is
the lack of supportive RCT data. The RCTs that have tested
whether intensiﬁed therapy according to PFT improvesify the patient at lower risk for cardiovascular events after percutaneous coronary
nists will be attenuated. In elective PCI, selective use in patients with higher predicted
d be considered, weighing the absolute bleeding hazard. Dashed arrows illustrate
U ¼ P2Y12 reaction unit. Figure illustration by Craig Skaggs.
Figure 2
Cardiovascular Risk After PCI According to the Level
of On-Clopidogrel Platelet Reactivity
First quartile or quintile used as a referent. Hazard ratio for major adverse cardiac
events per quartile of on-treatment reactivity (Brar et al. [7]) or calculated odds
ratio for 30-day deﬁnite/probable stent thrombosis per quintile (ADAPT-DES [9]) is
plotted against the average PRU of the given quartile or quintile. In ADAPT-DES, the
upper bound was not reported, and the average PRU of the 5th quintile is
estimated. Bubble size is proportional to the number of patients in each bin.
ADAPT-DES ¼ Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents;
other abbreviations as in Figure 1.
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interventions and the populations that were enrolled, which
were primarily low-risk patients undergoing nonurgent PCI.
An appropriately-powered trial in an ACS population will
necessarily be very large, expensive, and challenging to
complete. In the case of the CYP2C19 genotype, dose
adjustment or selection of alternative agents in the setting of
renal dysfunction or drug–drug interactions that similarly
inﬂuence pharmacokinetics are commonly recommended
without RCT data for drugs other than clopidogrel. In the
absence of a deﬁnitive trial, we do know that OTR is
a unique risk marker because of the following: 1) it directly
measures the therapeutic action of the P2Y12 antagonists; 2)
it correlates strongly with clopidogrel and prasugrel active
metabolite levels; 3) it has been successfully used to predict
the clinical beneﬁt of the newer P2Y12 antagonists; 4) it is
predictive of clinical outcome on clopidogrel, with thresh-
olds identiﬁed to determine risk; and 5) it is highly
actionable. The CYP2C19 genotype shares many of these
characteristics. These data support the use of these tests in
clinical practice on an individualized basis, taking into
account the absolute thrombotic risk of the particular indi-
vidual and the bleeding risk with more intensiﬁed anti-
platelet therapy.
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Are Platelet Function
and Genetic Testing for
Clopidogrel Hyporesponsiveness
Useful in Clinical Practice?
Ajay J. Kirtane, MD, SM, Gregg W. Stone, MDAmong the many advances in medicine in the last 3 decades,
the broad and effective application of evidence-based
medicine has arguably had the greatest impact in
improving patient outcomes. Cardiovascular medicine has
a rich tradition of generating observational and randomized
data through which we inform our decisions. However, in
the present era, we are increasingly faced with the evaluation
of iterative therapeutic options for well-characterized (and
generally well-treated) disease states. Many of these newer
therapies provide smaller incremental gains over predecessor
therapiesdgains that must be considered in the context of
clinically relevant side effects. Thus, the net clinical utility of
new therapies requires a careful assessment of the overall and
absolute beneﬁts and harms applied to patients across the
spectrum of risk.
These concepts are highly relevant when evaluating the
role of platelet reactivity and genetic testing for tailoring
antiplatelet therapies for patients with acute coronary syn-
dromes (ACS) or those undergoing percutaneous coronary
intervention (PCI). From a clinical perspective, the greatest
potential utility of these tests lies in their ability to rationally
individualize therapeutic options for patients. The combi-
nation of aspirin and the thienopyridine clopidogrel has
for over a decade been a cornerstone in the treatment of both
ACS and PCI patients. These agents act in concert to
ameliorate the prothrombotic processes stimulated by plaque
rupture and vessel injury, which occur either spontaneously
(in ACS) or iatrogenically (with PCI) (1,2). Observational
and randomized trial data have clearly demonstrated thatmore potent antiplatelet therapies (or more accurately,
greater inhibition of platelet function) can improve ischemic
outcomes for both groups of patients (3–6). However, more
potent antiplatelet therapies are also associated with greater
risks of bleeding complications, which may offset the
beneﬁts of these agents (7). Thus, identiﬁcation of
individuals for whom escalation of antiplatelet therapy
might prevent an ischemic event from occurring is an
attractive way of personalizing patient care, provided that
the increased bleeding risk of such a therapy can be
avoided. It is in this clinical context that we must evaluate
the overall utility of genotype and platelet reactivity testing.
The therapeutic effectiveness of clopidogrel is conditioned
upon its variability in antiplatelet effect, which is inﬂuenced
by numerous factors both genotypic (e.g., speciﬁc mutations
in cytochrome P450 [CYP] 2C19), and phenotypic (e.g.,
patient presentation with ACS, poor adherence) in nature. It
has been demonstrated unequivocally that genotype testing
for mutations in the clopidogrel metabolic pathway can
identify patients who are poor responders and are at higher
risk for subsequent ischemic events (8). Either increasing the
dose of clopidogrel or substitution of other more potent
agents not affected by the CYP2C19 pathway in patients
with these mutations can lower platelet reactivity (9,10).
Similarly, testing for the phenotype of platelet
hyporesponsiveness can identify patients at higher risk for
ischemic events (3,11), and escalation of treatment in
these individuals can lower platelet reactivity (12–14). So,
despite undisputed evidence of the science behind both
genetic and platelet reactivity testing, why is there
controversy regarding the use of these tests to inﬂuence
clinical decision making?
There are 4 critical issues germane to the discussion of the
clinical role of genetic and/or platelet reactivity testing: 1)
the relatively high overall prevalence of “abnormal” testing;
2) the relatively low overall incidence of adverse ischemic
events, particularly stent thrombosis (ST), which might be
prevented through a testing-based strategy; 3) the ability of
more potent antiplatelet regimens to reduce or eliminate
adverse ischemic events in patients at risk; and 4) the
potential deleterious side effects (bleeding) of more potent
antiplatelet therapies. Both abnormal genotype and platelet
reactivity testing are powerful independent predictors of
adverse ischemic events among patients treated with clopi-
dogrel (hazard ratio 3- to 4-fold for ST in most studies).
However, because the prevalence of the “risk factor” of high
on-treatment platelet reactivity is relatively high (on the
order of approximately 20% to 40%), a large number of
patients who are either carriers and/or have high on-
treatment platelet reactivity do not ultimately have
ischemic events (11). Moreover, the etiology of ST and
ischemic events is multifactorial, and even near abolition
of adenosine diphosphate–induced platelet activation
does guarantee their elimination. Thus, the combination
of the relatively common occurrence of high on-
treatment reactivity (or CYP2C19 carrier status) with
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S30a low overall incidence of eventsdcoupled with only
partial efﬁcacy of the pharmacological responses
availabledresults in a large number of patients that must
be treated to prevent 1 event. For example, in the large
ADAPT-DES (Assessment of Dual AntiPlatelet
Therapy With Drug Eluting Stents) study evaluating the
utility of platelet reactivity testing following PCI, the
risk of a deﬁnite or probable ST event at 1 year was 1.3%
among patients with high on-treatment platelet reactivity
compared with 0.5% among patients without high on-
treatment reactivity (11). Even assuming that all ST
events attributable to high on-treatment activity could be
eliminated by more potent antiplatelet therapy, one
would still need to treat 125 patients in order to prevent
a single ST event. The number needed to treat would
further rise to 250 assuming 50% efﬁcacy of the new
therapy, which still may be optimistic.
Nonetheless, given the profound clinical impact of
subsequent ischemic events (especially ST), this large
number needed to treat might be acceptable in triggering
a modiﬁcation of antiplatelet therapy if the change in
therapy had no adverse consequences (such as increased
bleeding or costs). Of course, if such an agent existed, it would
obviate the need for either genotype or platelet reactivity
testing, as all patients could just be treated with this hypo-
thetical agent rather than clopidogrel. At present, however,
such a therapy does not exist. Dose increases in clopidogrel
can partially overcome high on-treatment reactivity in
carriers (but not homozygotes) of mutations in the CYP2C19
allele (10), but increased dosing may also increase the risk of
bleeding with adverse clinical consequences comparable to
(and therefore counterbalancing) the reduction in ST (6).Figure 1 Possible Treatment Algorithm
Possible (unstudied) treatment algorithm utilizing testing to modify treatment in high-risk p
syndrome.More potent agents such as prasugrel and ticagrelor can
clearly lower platelet reactivity even in homozygotes but
have both been associated with an increased risk of non–
coronary artery bypass graft–related major bleeding
compared with clopidogrel (4,5). Thus, in patients for
whom a therapeutic switch is being considered, the high
number needed to treat to prevent ischemic events in
concert with the potential harm of bleeding complications
(and cost) does not suggest a favorable balance for most
patients, particularly those at lower ischemic risk (e.g., non-
ACS). It is thus not surprising that compared with
standard-dose clopidogrel, either higher doses of clopidogrel
or administration of prasugrel did not substantially reduce
ischemic events in 3 randomized trials of patients with high
on-treatment platelet reactivity to clopidogrel following
successful PCI (12–14).
The most promising role for either genotype or platelet
reactivity testing may paradoxically lie among patients who
already meet traditional indications for escalation of anti-
platelet therapy. In the ADAPT-DES study, the use of
platelet reactivity testing was more predictive of ST among
clopidogrel-treated ACS patients than those without ACS
(11). Further, the overall incidence of ischemic events
including ST is demonstrably higher among ACS patients,
which results in a greater absolute risk reduction (or lower
number needed to treat) from a treatment modiﬁcation. At
present, based on large-scale randomized trials in which
genetic and platelet function testing was not utilized to
direct therapy (4,5), the standard of antiplatelet care for
patients with the higher thrombotic risk of ACS is either
prasugrel or ticagrelor. Both agents reduce ischemic
complications (including ST) among ACS patients, albeit atatients for whom more potent antiplatelet therapy is planned. ACS ¼ acute coronary
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bleeding complications (4,5), which has slowed their uptake
in clinical practice. Genotype or platelet reactivity testing in
this patient population might be able to identify those ACS
patients with an adequate response to clopidogrel who do
not require the more potent agents, and who thus might
beneﬁt by reduced bleeding risk (Fig. 1). Additionally, this
approach would be attractive from a cost standpoint,
given that clopidogrel is widely available in generic form. Of
course, such an approach requires validation in an
appropriately powered randomized trial before it should be
adopted in clinical practice.
One additional use of platelet reactivity testing could be in
the identiﬁcation of patients at a greater risk of bleeding
complications on any P2Y12 inhibitor (including clopi-
dogrel). Prior data derived from smaller patient series have
demonstrated an association between low on-treatment
platelet reactivity and bleeding events (15). In the large-
scale ADAPT-DES study, patients in the lowest quintile
of on-treatment platelet reactivity were at a greater risk of
major bleeding complications compared with patients with
higher levels of on-treatment reactivity (16). Preliminary
data from 300 ACS patients treated with prasugrel who
were tested for low on-treatment reactivity and accordingly
switched to clopidogrel if on-treatment reactivity was
indeed too low, demonstrated a lower rate of minor
bleeding following the down-titration of antiplatelet
therapy (17). Whether broader implementation of this
strategydnamely, titration of antiplatelet effect within
a “therapeutic window” using platelet function testing to
ensure that platelets are adequately inhibited to prevent
ischemic complications but not overinhibited so as to
predispose to bleeding complicationsdwill result in
optimal patient outcomes is currently unknown.
In conclusion, it is abundantly evident that genotypic and
platelet reactivity testing has demonstrated great promise in
the risk stratiﬁcation of patients requiring dual antiplatelet
therapy. The critical issue relates to the way in which we
as clinicians utilize these data in order to inform clinical
decision making for our patients. In the absence of pro-
spective clinical evidence supporting therapeutic modiﬁca-
tions based upon either genotypic or platelet reactivity
testing, the practical utility of such testing in routine
clinical practice is tantalizing at present, but nonetheless
speculative.
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